Clearside Biomedical

Clearside Biomedical PEG

Delisted

The PEG Ratio (Price/Earnings-to-Growth) of Clearside Biomedical (CLSD) as of Nov 20, 2026 is -0.01. In the previous year, PEG Ratio (Price/Earnings-to-Growth) was -0.03 — a change of -77.87% (higher).

PEG

-0.01

YoY

-77.87%

Last updated:

PEG Ratio (Price/Earnings-to-Growth) of Clearside Biomedical is 2024 -0.01 . PEG Ratio (Price/Earnings-to-Growth) of Clearside Biomedical was 2023 -0.03 . It decreases by -77.87% higher compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clearside Biomedical Stock analysis

What does Clearside Biomedical do? Clearside Biomedical, Inc. generates revenue through the development of drug therapies for blinding eye diseases, targeting the retina, choroid, and sclera. The company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide administered via suprachoroidal injection. This clinical stage biopharmaceutical firm focuses on treating conditions affecting these specific eye components to restore or preserve vision. The business model relies on advancing its proprietary therapies through clinical development rather than immediate commercial sales. By concentrating on the retina, choroid, and sclera, Clearside Biomedical, Inc. addresses critical anatomical areas involved in visual health. The company operates from its headquarters in Alpharetta, Georgia, with a dedicated team supporting its research and development efforts. Financial viability is tied to the successful progression of its drug candidates, particularly XIPERE, which utilizes a unique delivery method for triamcinolone acetonide. The firm engages in the biopharmaceutical sector by developing treatments for diseases that impact the structural and functional integrity of the eye. Its strategy centers on innovation in drug formulation and administration to treat blinding conditions effectively. Clearside Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clearside Biomedical stock

PEG Ratio (Price/Earnings-to-Growth) of Clearside Biomedical is -0.01 in 2024.

PEG Ratio (Price/Earnings-to-Growth) of Clearside Biomedical changed from -0.03 to -0.01, representing a -77.87% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) Clearside Biomedical since 2006 – with annual values, charts, and detailed analysis.

The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.

PEG = P/E Ratio / Expected Annual EPS Growth Rate

To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).

A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s Clearside Biomedical with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Clearside Biomedical

All Key Metrics — Clearside Biomedical